Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04878432
Title STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals

myelodysplastic syndrome


Azacitidine + Decitabine and Cedazuridine + Sabatolimab

Azacitidine + Decitabine + Sabatolimab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.